monoclonal CD-20 antibodies

PreclinicalSmall molecule

monoclonal CD-20 antibodies is one of 36 small molecule programs targeting Multiple Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

1 2

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 3

Zyrtec

KKenvue Brands

Phase 3

1 4

Vumerity

Biogen

Phase 3

4 5

Clemastine Fumarate

Novartis

Phase 3

2 6

Activated Charcoal

Sanofi

Phase 3

1 7

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 8

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 9

PBR06

UUniversity Hospital, Bordeaux

Phase 3

3 10

IMU-838

IImmunic AG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Not yet recruiting

Multiple Sclerosis

NCT07149662

Clinical

Trials by Indication[1]

Multiple Sclerosis1 trial

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy

Not yet recruiting·RRegion Stockholm··NCT07149662·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for monoclonal CD-20 antibodies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — monoclonal CD-20 antibodies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for monoclonal CD-20 antibodies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Stockholm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRegion Stockholm

monoclonal CD-20 antibodies

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News